These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6201211)

  • 1. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
    Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
    Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
    Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
    Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
    Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
    Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
    Presant CA; Berger NA; Klahr C; Phillips GL
    Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
    Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
    Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
    Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
    J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
    Champlin R; Jacobs A; Gale RP; Boccia R; Elashoff R; Foon K; Zighelboim J
    Lancet; 1984 Apr; 1(8382):894-6. PubMed ID: 6200742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
    Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
    Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
    Omura GA; Vogler WR; Lefante J; Silberman H; Knospe W; Gordon D; Jarrell R
    Cancer; 1982 Apr; 49(8):1530-6. PubMed ID: 7039813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
    Jehn U; Heinemann V
    Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemotherapy for acute myelogenous leukemia.
    Gale RP; Foon KA; Cline MJ; Zighelboim J
    Ann Intern Med; 1981 Jun; 94(6):753-7. PubMed ID: 6940466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
    Urbanitz D; Büchner T; Pielken H; Koch P; Ludwig WD; Maschmeier G; Heinecke A; van de Loo J
    Haematol Blood Transfus; 1987; 30():64-8. PubMed ID: 3305224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.